Xilio Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Xilio Therapeutics, Inc. (XLO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $640.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-12
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $3.94M.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$3.30M.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$21.27M.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $15.38M.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$5.84M.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $453.00K, a 259.52% increase from fiscal 2020.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was $126.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $640.00K 10-Q · filed 2026-08-12 | -$20.64M derived: sum of 3 quarters · filed 2026-08-12 | -$5.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$3.30M 10-Q · filed 2026-05-12 | -$24.57M derived: sum of 2 quarters · filed 2026-05-12 | -$9.20M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2025-12-31 | -$21.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$5.89M derived: sum of 2 quarters · filed 2026-03-23 | -$5.84M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $15.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $15.43M 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $50.00K 10-Q · filed 2025-08-14 | |||
| 2021-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $453.00K 10-K · filed 2023-03-02 | ||
| 2021-09-30 | $450.00K 10-Q · filed 2021-12-02 | |||
| 2020-12-31 | $126.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |